Filtered By:
Condition: Thrombosis
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 145 results found since Jan 2013.
Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data
In conclusion, both virus-based COVID-19 vaccines show more SAEs than BNT, but the frequency of the SAE type in the different age groups differs, suggesting that the mechanisms responsible of SAEs overlap only partly.PMID:34710832 | PMC:PMC8547775 | DOI:10.1016/j.jaut.2021.102742
Source: Journal of Autoimmunity - October 28, 2021 Category: Allergy & Immunology Authors: Luigi Cari Mahdieh Naghavi Alhosseini Paolo Fiore Sabata Pierno Sabrina Pacor Alberta Bergamo Gianni Sava Giuseppe Nocentini Source Type: research
Acute Ischaemic Stroke Incidence after Coronavirus Vaccine in Indonesia: Case Series
Curr Neurovasc Res. 2021 Sep 26. doi: 10.2174/1567202618666210927095613. Online ahead of print.ABSTRACTCoronavirus disease-19 (COVID-19) is an infectious disease with high morbidity and mortality rates. Indonesia had reported a 2.8% of mortality rate up to June 2021. A strategy to control the virus spreading is by vaccination. The Indonesian Food and Drug Monitoring Agency had approved the use of CoronaVac, an inactivated virus vaccine developed by Sinovac. Most adverse events following immunization (AEFI) for CoronaVac are mild, and the most common symptoms are injection-site pain, headache, and fatigue. Neurovascular adv...
Source: Current Neurovascular Research - September 28, 2021 Category: Neurology Authors: Rakhmad Hidayat Dinda Diafiri Ramdinal Aviesena Zairinal Ghafur Rasyid Arifin Faiza Azzahroh Nita Widjaya Devi Nurfadila Fani Taufik Mesiano Mohammad Kurniawan None Al Rasyid Astuti Giantini Salim Haris Source Type: research
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Vaccine-Induced Immune Thrombotic Thrombocytopenia with Concurrent Arterial and Venous Thrombi Following Ad26.COV2.S Vaccination
We describe a case of simultaneous venous and arterial thrombosis associated with severe thrombocytopenia following Ad26.COV2.S vaccination.
Source: Journal of Stroke and Cerebrovascular Diseases - September 18, 2021 Category: Neurology Authors: Andreas Charidimou, Shilpa Samudrala, Anna M. Cervantes-Arslanian, J. Mark Sloan, Hormuzdiyar H. Dasenbrock, Ali Daneshmand Tags: Case Report Source Type: research
Treatment of ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia Related Acute Ischemic Stroke
We report clinical, laboratory, imaging findings and treatment in a 51-year-old female presenting with acute left middle cerebral artery (MCA) occlusion 7 days after the first dose of ChAdOx1 nCoV-19 vaccine.
Source: Journal of Stroke and Cerebrovascular Diseases - August 28, 2021 Category: Neurology Authors: Jana Kenda, Dimitrij Lovri č, Matevž Škerget, Nataša Milivojević Tags: Short Communication Source Type: research
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine: COMMENT: COMMENT from Gruel et al.: RESPONSE from Kahn et al
J Thromb Haemost. 2021 Jul 17. doi: 10.1111/jth.15467. Online ahead of print.ABSTRACTWe acknowledge the commentary of Gruel et al. on our recent letter [1] and are pleased that the authors agree that IdeS may be a potential treatment option for the rare but potentially severe IgG-mediated platelet activation observed in complications to vaccination with ChAdOx1 nCoV-19. It is apparent that our respective but distinct expertise with regard to IdeS has led us to develop this hypothesis in parallel. As we clearly cited in our original letter these authors have previously contributed important evidence that IdeS may be benefic...
Source: Thrombosis and Haemostasis - July 17, 2021 Category: Hematology Authors: Fredrik Kahn Oongh Shannon Lars Bj örck Source Type: research
Flu jab may reduce severe effects of Covid, suggests study
Analysis of 75,000 coronavirus patients found fewer major health problems among people with flu jabCoronavirus – latest updatesSee all our coronavirus coveragePeople who are vaccinated against influenza may be partly protected against some of the severe effects of coronavirus, and be less likely to need emergency care, according to a major study.The analysis of nearly 75,000 Covid patients found significant reductions in stroke, deep vein thrombosis (DVT) and sepsis, and fewer admissions to emergency departments and intensive care units, among those who had been given the flu jab.Continue reading...
Source: Guardian Unlimited Science - July 12, 2021 Category: Science Authors: Ian Sample Science editor Tags: Medical research Coronavirus Vaccines and immunisation Health UK news Source Type: news
Suggested treatment of serious complications to Covid-19 vaccination with IdeS, a bacterial antibody-cleaving enzyme
J Thromb Haemost. 2021 Jun 24. doi: 10.1111/jth.15433. Online ahead of print.ABSTRACTSeveral recent reports have independently described a rare thrombosis with thrombocytopenia syndrome (TTS) post vaccination with ChAdOx1 nCoV-19. In J. Thromb. Haemost., Ankerlund Blauenfeldt et al. [1] described the clinical presentation of a case of fatal acute ischemic stroke associated with profound thrombocytopenia. The pathogenesis behind this case may involve mechanisms similarly to autoimmune heparin-induced thrombocytopenia (HIT) since anti-platelet factor 4(PF-4) antibodies were detected in the patient plasma.PMID:34165239 | DOI:10.1111/jth.15433
Source: Thrombosis and Haemostasis - June 24, 2021 Category: Hematology Authors: Fredrik Kahn Oonagh Shannon Lars Bj örck Source Type: research
